An index of frontier and emerging AI labs.
Bio / AI drug discovery
AI-driven drug discovery lab applying generative models, deep learning, and the Pharma.AI platform to target identification and molecule generation. HKEX-listed (3696) in 2025; advanced one of the first fully AI-designed drugs to mid-stage human trials.
| Name | Insilico Medicine |
|---|---|
| Space | Bio / AI drug discovery |
| Founded | 2014 |
| Latest valuation | — |
| Stage | — |
| Status | active |
| HQ | Boston / Hong Kong |
| Founders | Alex Zhavoronkov |
| Website | https://insilico.com |
| Careers | https://insilico.com/careers |
| — | |
| X / Twitter | — |
No funding events recorded.
No founders recorded yet. Submit info.
| Date | Type | Title | Source |
|---|---|---|---|
| 2026-06-03 | added | Insilico Medicine added to tracker | — |
No sources cited.
| Lab | Valuation | Founded |
|---|---|---|
| Enveda | — | 2019 |
| Helical | — | 2024 |
| Reliant AI | — | 2023 |
| Isomorphic Labs | >$15B | 2021 |
| Xaira Therapeutics | ~$4B | 2024 |
| insitro | ~$2.5B | 2018 |
| Generate Biomedicines | ~$2B | 2018 |
| Recursion | ~$1.75B (mkt cap) | 2013 |